Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Open Access
- 24 October 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Advances in Therapy
- Vol. 35 (11), 1763-1774
- https://doi.org/10.1007/s12325-018-0805-y
Abstract
Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the “gold standard” for evaluating the safety and efficacy of new therapeutic agents, necessarily strict inclusion and exclusion criteria mean that trial populations are often not representative of the patient populations encountered in clinical practice. Real-world studies may use information from electronic health and claims databases, which provide large datasets from diverse patient populations, and/or may be observational, collecting prospective or retrospective data over a long period of time. They can therefore provide information on the long-term safety, particularly pertaining to rare events, and effectiveness of drugs in large heterogeneous populations, as well as information on utilization patterns and health and economic outcomes. This review focuses on how evidence from real-world studies can be utilized to complement data from RCTs to gain a more complete picture of the advantages and disadvantages of medications as they are used in practice. Funding: Sanofi US, Inc.Keywords
Funding Information
- Sanofi
This publication has 52 references indexed in Scilit:
- Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological OverviewPLoS Medicine, 2011
- EBM, HTA, and CER: Clearing the ConfusionThe Milbank Quarterly, 2010
- Explanatory and Pragmatic Attitudes in Therapeutical TrialsJournal of Clinical Epidemiology, 2009
- Patient‐directed titration for achieving glycaemic goals using a once‐daily basal insulin analogue: an assessment of two different fasting plasma glucose targets ‐ the TITRATETM studyDiabetes, Obesity and Metabolism, 2009
- Improving the reporting of pragmatic trials: an extension of the CONSORT statementBMJ, 2008
- The usage of a simplified self‐titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE™ 303 studyDiabetes, Obesity and Metabolism, 2007
- Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force ReportValue in Health, 2007
- A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose‐lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) StudyDiabetic Medicine, 2006
- Randomized Controlled Trials: Do They Have External Validity for Patients With Multiple Comorbidities?Annals of Family Medicine, 2006
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999